News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,326 Results
Type
Article (2445)
Company Profile (39)
Press Release (35842)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (14128)
Career Advice (78)
Deals (2081)
Drug Delivery (9)
Drug Development (4103)
Employer Resources (10)
FDA (431)
Job Trends (764)
News (20149)
Policy (1053)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (144)
Allergies (6)
Alliances (3473)
ALS (4)
Alzheimer's disease (46)
Antibody-drug conjugate (ADC) (18)
Approvals (433)
Artificial intelligence (11)
Autoimmune disease (3)
Automation (1)
Bankruptcy (12)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (29)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (20)
Cancer (149)
Cardiovascular disease (5)
Career advice (65)
Career pathing (1)
CAR-T (16)
Cell therapy (48)
Cervical cancer (2)
Clinical research (3190)
Collaboration (94)
Compensation (51)
COVID-19 (180)
CRISPR (7)
C-suite (31)
Cystic fibrosis (2)
Data (123)
Denatured (3)
Depression (3)
Diabetes (10)
Diagnostics (465)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (15)
Drug pricing (7)
Duchenne muscular dystrophy (12)
Earnings (4250)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6063)
Executive appointments (99)
FDA (479)
Featured Employer (3)
Funding (79)
Gene editing (14)
Gene therapy (21)
GLP-1 (60)
Government (149)
Healthcare (704)
Huntington's disease (3)
IgA nephropathy (4)
Immunology and inflammation (17)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (990)
IRA (7)
Job creations (290)
Job search strategy (63)
Kidney cancer (4)
Labor market (4)
Layoffs (39)
Leadership (1)
Legal (212)
Liver cancer (6)
Lung cancer (15)
Lymphoma (4)
Management (4)
Manufacturing (20)
MASH (4)
Medical device (307)
Medtech (307)
Mergers & acquisitions (1165)
Metabolic disorders (34)
Multiple sclerosis (9)
Neurodegenerative disease (9)
Neuropsychiatric disorders (3)
Neuroscience (95)
NextGen: Class of 2025 (352)
Non-profit (153)
Northern California (383)
Now hiring (4)
Obesity (16)
Opinion (15)
Ovarian cancer (10)
Pain (10)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (2)
Patents (23)
Patient recruitment (5)
Peanut (1)
People (5677)
Pharmaceutical (5)
Phase I (1376)
Phase II (1599)
Phase III (850)
Pipeline (84)
Policy (12)
Postmarket research (30)
Preclinical (598)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (13)
Rare diseases (24)
Real estate (420)
Recruiting (5)
Regulatory (809)
Reports (6)
Research institute (142)
Resumes & cover letters (9)
RNA editing (1)
Schizophrenia (12)
Series A (25)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (372)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (489)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1815)
Vaccines (28)
Venture capitalists (8)
Weight loss (12)
Women's health (1)
Worklife (1)
Date
Today (26)
Last 7 days (87)
Last 30 days (266)
Last 365 days (2568)
2025 (863)
2024 (2611)
2023 (2858)
2022 (3753)
2021 (4049)
2020 (3473)
2019 (2062)
2018 (1555)
2017 (1795)
2016 (1625)
2015 (1836)
2014 (1372)
2013 (1189)
2012 (1397)
2011 (1332)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (15)
Asia (1874)
Australia (298)
California (879)
Canada (138)
China (41)
Colorado (21)
Connecticut (10)
Delaware (4)
Europe (3835)
Florida (44)
Georgia (5)
Idaho (3)
Illinois (14)
India (1)
Indiana (33)
Japan (8)
Kansas (12)
Maryland (26)
Massachusetts (318)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (3)
New Hampshire (2)
New Jersey (71)
New York (50)
North Carolina (91)
Northern California (383)
Ohio (26)
Oklahoma (2)
Oregon (5)
Pennsylvania (54)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (372)
Tennessee (2)
Texas (75)
Utah (2)
Virginia (6)
Washington D.C. (1)
Washington State (54)
Wisconsin (6)
38,326 Results for "alligator bioscience".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alligator Bioscience AB Reports Financial Results for Q1 2025 and Provides a Business Update
April 24, 2025
·
3 min read
Press Releases
Alligator Bioscience Announces Initiation of HLX22 Phase 2 Trial in Breast Cancer by Shanghai Henlius Biotech, Inc.
April 23, 2025
·
1 min read
Layoffs
Alligator Axes 70% of Staff Amid ‘Capital Constraints,’ Renews Pancreatic Cancer Focus
Alongside the layoffs, Alligator will also suspend work on all of its earlier-stage assets and devote its resources to lead candidate mitazalimab, being developed for the frontline treatment of metastatic pancreatic cancer.
December 3, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Alligator Bioscience’s Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology
Alligator Bioscience announced the publication of positive Phase 2 data on its lead drug candidate mitazalimab in first line metastatic pancreatic cancer in The Lancet Oncology.
June 3, 2024
·
5 min read
Press Releases
Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies
November 19, 2024
·
1 min read
Drug Development
Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting
Alligator Bioscience (STO:ATORX) today announced that two clinical abstracts on its lead drug candidate mitazalimab, a best-in-class CD40 agonist, in first line metastatic pancreatic cancer will be presented (abstracts 2569 and 4133) in a poster presentation session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL and online during May 31-June 4.
May 23, 2024
·
5 min read
Press Releases
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
October 30, 2024
·
6 min read
Business
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
Alligator Bioscience AB and Aptevo Therapeutics today announced positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors likely to express the tumor antigen 5T4.
March 7, 2024
·
8 min read
Press Releases
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
September 13, 2024
·
7 min read
Press Releases
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
September 16, 2024
·
9 min read
1 of 3,833
Next
